August 21, 2025Open Access Figure S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
Key Points
- Targeting both bcl-xl and mcl-1 with bh3 mimetics significantly enhances anti-cancer effects in AR-V7-expressing CRPC models.
- Single-agent activity of bh3 mimetics was evaluated across various cell lines, including lncap95, vcap-cr, and 22rv1 cells.
- The research method involved comparative analysis of cell viability and response to drug treatment under controlled conditions.
- The findings support potential dual-targeting strategies to boost treatment efficacy against resistant prostate cancer.
Abstract
Figure S2 shows the single agent activity of BH3 mimetics across LNCaP95, VCaP-CR, and 22Rv1 cells.
Brim et al. (Thu,) studied this question.
Table S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models
2025